Download video

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

64 views

Targeted Oncology

8 years ago

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment
2:19
Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment
by Targeted Oncology
Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments
1:28
Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments
by Targeted Oncology
Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response
0:57
Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response
by Targeted Oncology
Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor
2:34
Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor
by OBRoncology
Dr. Jeffrey Weber, MD, PhD at Laura \& Isaac Perlmutter Cancer Center and Academy of Immuno-Oncology
6:16
Dr. Jeffrey Weber, MD, PhD at Laura \& Isaac Perlmutter Cancer Center and Academy of Immuno-Oncology
by Society for Immunotherapy of Cancer
Dr. Jeffrey Weber on the Keys to Targeted Treatments
1:23
Dr. Jeffrey Weber on the Keys to Targeted Treatments
by Targeted Oncology
Jeffrey Weber, MD, PhD: The Association Between Durable Response and Low Disease Burden
2:20
Jeffrey Weber, MD, PhD: The Association Between Durable Response and Low Disease Burden
by Targeted Oncology
Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination
1:01
Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination
by Targeted Oncology
Dr. Weber on Emerging Therapies in Melanoma
0:49
Dr. Weber on Emerging Therapies in Melanoma
by OncLive
Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma
2:26
Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma
by OBRoncology
Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results
1:26
Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results
by OBRoncology
Jeffrey Weber, MD, PhD: Predicting Durable Responses to Targeted Therapy
1:44
Jeffrey Weber, MD, PhD: Predicting Durable Responses to Targeted Therapy
by Targeted Oncology
Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies
1:23
Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies
by OBRoncology
Dr. Jeffrey Weber on Optimal Therapy Sequences in Advanced Melanoma
1:44
Dr. Jeffrey Weber on Optimal Therapy Sequences in Advanced Melanoma
by OncLive
Jeffrey Weber, MD, PhD: Second-Line Therapy
1:17
Jeffrey Weber, MD, PhD: Second-Line Therapy
by Targeted Oncology
Phase I Clinical Trials, with Jeffrey S. Weber, MD, PhD
10:57
Phase I Clinical Trials, with Jeffrey S. Weber, MD, PhD
by ASCO Podcasts
Jeffrey Weber on the Role of Oncology Nurses in Treating Patients With Checkpoint Inhibitors
0:47
Jeffrey Weber on the Role of Oncology Nurses in Treating Patients With Checkpoint Inhibitors
by OncLive
Meet Oncologist Dr. Jeffrey Weber
2:21
Meet Oncologist Dr. Jeffrey Weber
by NYU Langone Health
Clinical trials investigating the treatment of melanoma
1:13
Clinical trials investigating the treatment of melanoma
by VJOncology
Treatment Beyond Melanoma Progression
6:08
Treatment Beyond Melanoma Progression
by OncLive